I did a Medicine and Neuroscience BSc at Cambridge University and Clinical Medicine at UCL. I worked as a medical and psychiatric doctor in North London from 2004-10.
In 2009 I did an MSc in the Philosophy of Mental Disorder at KCL, and from 2010-14, I did my PhD at the Wellcome Centre for Human Neuroimaging at UCL, supervised by Prof Karl Friston. From 2014-18, I was an NIHR Clinical Lecturer in Psychiatry at UCL (Division of Psychiatry and Institute of Cognitive Neuroscience), in Prof Jon Roiser's group.
In 2016 I took up a Bogue Fellowship to study at Yale University in Dr Alan Anticevic's group. I've also enjoyed fruitful collaborations with Prof Oliver Howes (KCL, Imperial), Prof Neil Burgess (UCL) and Prof Mark Edwards (KCL).
From 2018-22 I was an MRC Skills Development Fellow in Prof Janaina Mourao-Miranda's group in the Centre for Medical Image Computing and Max Planck UCL Centre for Computational Psychiatry and Ageing Research. I am currently a Future Leaders Fellow in the Institute of Cognitive Neuroscience (Division of Psychiatry) and Centre for Medical Image Computing (Dept of Computer Science). My UCL webpage is here.
From 2016-21 I was a member of the Gatsby/Wellcome Neuroscience Project, whose goal was to update the neuroscience content of the training curriculum for psychiatrists in the UK.
Since 2014 I have co-organised (with Dr Xiaosi Gu: now at Mount Sinai) the UCL Computational Psychiatry Course: the first such course in the world. It provides a two day introduction to the computational modelling of behaviour in psychiatric research, and the slides and audio of past lectures are online. As of 2023, the course became the Computational Psychiatry Conference. Dr Gu and I are also Co-Editors-in-Chief of the open-access journal Computational Psychiatry (CPsy).
I do an outpatient clinic in the Neuropsychiatry department at the National Hospital for Neurology and Neurosurgery, London
I also see adult patients (both general psychiatry and neuropsychiatry) privately for Bloomfield Health
There may be two major biological pathologies in schizophrenia:
i) dysfunction of NMDA receptors, which may be compensated by interneuron downregulation, causing an imbalance between excitatory and inhibitory function (so-called 'E/I imbalance') and loss of 'signal-to-noise' in higher hierarchical brain areas such as prefrontal cortex and hippocampus.
ii) increased synthesis and release of dopamine in the striatum.
I use models of brain function to understand how these changes might contribute to schizophrenia and psychosis. Examples include:
i) Modelling perception, action & cognition:
The brain may perform (or approximate) Bayesian inference on the causes of its sensory data (e.g. by updating top-down predictions with bottom-up prediction errors). Imprecise prior beliefs could cause various phenomena in schizophrenia (Adams et al. 2013, Front Psychiatry). Altered circuit properties could also affect belief stability and 'noise' in decision-making (e.g. in the 'beads' task; Adams et al. 2018, J Neurosci), and delusions could arise due to habitual and affective influences on a noisy cognitive system (Adams et al. 2021, Schiz Res).
ii) Modelling imaging data:
Dynamic causal modelling (DCM) uses biophysical models of imaging data to estimate circuit properties like E/I in different brain areas, or connectivity between them. We found a loss of neural gain modulation in prefrontal cortex in schizophrenia (Ranlund, Adams, et al. 2016, Hum Brain Mapp) and evidence for a loss of pyramidal cell excitability in three separate EEG paradigms in schizophrenia (Adams et al. 2022, Biol Psychiatry). Interestingly, in this study we also found that symptoms such as hallucinations correlated with circuit disinhibition - this may mean that psychotic symptoms are the price the brain pays for trying to rebalance excitation and inhibition in its circuits. We have also found decreased coupling between hippocampus and mPFC during memory retrieval (Adams et al. 2020, Brain).
iii) Mapping behavioural models on to the brain:
Are our models of behaviour instantiated in the brain? We have tested whether behavioural model parameters correlate with E/I parameters from M/EEG models (Adams et al. 2016, Neuroimage) or dopamine 2/3 receptor availability from PET data (Adams et al., 2020, Cereb Cortex).
iv) Discovering new psychosis phenotypes:
My next project (2022-) aims to use both DCM and machine learning methods (applied to M/EEG data) to infer excitatory and inhibitory neuron pathology in individuals with schizophrenia and thus better target glutamatergic treatments early on in the disorder.